AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15780739
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (20 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Trial: 15780739
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (40 microg) for patients with CD4 cell counts < 350 cells/mm3
Trial: 15780739
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (20 microg) for patients with CD4 cell counts < 350 cells/mm3
Trial: 15780739
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (40 microg) for patients with HIV viral load < 10,000 copies/mL
Trial: 15780739
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (20 microg) for patients with HIV viral load < 10,000 copies/mL
Trial: 15780739
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (40 microg) for patients with HIV viral load > or = 10,000 copies/mL
Trial: 15780739
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (20 microg) for patients with HIV viral load > or = 10,000 copies/mL
Trial: 11919486
Drug: NVP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVP plus zidovudine (twice daily for 1 week)
Trial: 11919486
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose NVP alone
Trial: 7438350
Drug: Antiheart antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiheart antibody (AHA)
Trial: 7438350
Drug: Antiviral antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral antibody (AVA)
Trial: 7438350
Drug: Antiviral response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antiviral response to viral infections
Trial: 28504921
Drug: Plasminogen Activator
RxNorm normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasminogen Activator Inhibitor-1 (PAI-1)
Trial: 28504921
Drug: Homeostatic model
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostatic model assessment of insulin resistance
Trial: 19446890
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg daily, p.o.)
Trial: 17254831
Drug: Vaccine uptake
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine uptake among students with younger, male, or not literate family heads.
Trial: 17254831
Drug: Vaccine uptake
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine uptake among students from households with higher per-capita income.
Trial: 15658548
Drug: Vitrum osteomag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrum osteomag (2 tablets daily for 12 months)
Trial: 15658548
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1500 mg)
Trial: 11293926
Drug: Orocal D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orocal D3 (500 mg calcium and 400 IU vitamin D3) taken in two doses at 6-hour intervals
Trial: 11293926
Drug: Cacit vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cacit vitamin D3 (1000 mg calcium and 880 IU vitamin D3) taken as a single morning dose
Trial: 8196849
Drug: Piroxicam FDDF
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam FDDF 20 mg/day
Trial: 22461276
Drug: Noveon laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noveon laser treatment for onychomycosis
Trial: 10726910
Drug: Bezafibrate treatment
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate treatment (16 weeks)
Trial: 10726910
Drug: Bezafibrate treatment
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate treatment (8 weeks)
Trial: 9292071
Drug: Topical all‐trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical all‐trans retinoic acid (RA)
Trial: 9292071
Drug: Sodium lauryl
RxNorm normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lauryl sulphate (SLS) followed by topical all‐trans retinoic acid (RA)
Trial: 1606395
Drug: Intratracheal N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal N-acetylcysteine (5% N-acetylcysteine administered every 4 hours for one week)
Trial: 1606395
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (administered every 4 hours for one week)
Trial: 23136273
Drug: AAQ +
RxNorm normalized name: Abiraterone Acetate
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AAQ + AMX (artesunate amodiaquine with amoxicillin)
Trial: 10235025
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with stem cell support (induction with cyclophosphamide and taxol, followed by three high dose cycles of carboplatin, taxol, etoposide, and melphalane)
Trial: 10235025
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (as per AGO-Ovar-5-study)
Trial: 9112171
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml MMC
Trial: 9112171
Drug: 0.2 mg/ml
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/ml MMC
Trial: 30008787
Drug: Fermented Laminaria
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented Laminaria japonica (FST) 1.5 g/day for 6 weeks
Trial: 25401715
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 to 20 mg/d)
Trial: 18022546
Drug: Therapeutic cancer
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cancer vaccines (including inactivated tumor cells, heat shock protein vaccines, anti-ganglioside antibodies)
Trial: 31022313
Drug: Group cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive‐behavioral therapy with exposure (CBT ERP)
Trial: 26142612
Drug: Antidepressant continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant continuation (AD)
Trial: 26142612
Drug: Antidepressant discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant discontinuation (C)
Trial: 16208050
Drug: Modified Mini-Mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Mini-Mental State Examination (MMSE) administered to Group A (non-neurological illness)
Trial: 16208050
Drug: Modified Mini-Mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Mini-Mental State Examination (MMSE) administered to Group B (encephalopathy)
Trial: 10599952
Drug: Lidocaine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (600 mg + 5 microg/ml adrenaline)
Trial: 10599952
Drug: Articaine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine (600 mg + 5 microg/ml adrenaline)
Trial: 7867179
Drug: Control (medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (medical therapy only, n = 33)
Trial: 1784628
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg miglitol
Trial: 22052170
Drug: Intensive timing
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive timing induction chemotherapy
Trial: 22052170
Drug: Standard timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard timing induction chemotherapy
Trial: 22052170
Drug: Chemotherapy intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy intensification
Trial: 23806850
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg subcutaneous progesterone daily for 11 days
Trial: 23806850
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg subcutaneous progesterone daily for 11 days
Trial: 21138376
Drug: Low-dose SBE
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SBE (2,000 mg of SBE/day)
Trial: 21138376
Drug: High-dose SBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SBE (4,000 mg of SBE/day)
Trial: 21138376
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (1,140 mg of pinitol/day)
Trial: 21138376
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control (2,000 mg of lactose/day)
Trial: 11866010
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg x kg(‐1) tobramycin once-daily
Trial: 11866010
Drug: 3.3 mg
RxNorm normalized name: niacin 3.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 mg x kg(‐1) tobramycin thrice-daily
Trial: 2653044
Drug: Timolol 0.5%-Pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5%-Pilocarpine 4% twice a day
Trial: 2653044
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice a day plus Pilocarpine 4% three times a day
Trial: 134724
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (2 puffs, 0.02 mg per puff)
Trial: 134724
Drug: Isoprenaline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (2 puffs, 0.1 mg per puff)
Trial: 31454444
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy + Community Reinforcement Approach for Seniors (MET + CRA-S)
Trial: 30768121
Drug: BFP excision
RxNorm normalized name: pNF1-Blast Excised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFP excision with hydrodissection (15 mL of a vasoconstricting anesthetic solution)
Trial: 30768121
Drug: BFP excision
RxNorm normalized name: pNF1-Blast Excised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFP excision with 3 mL of lidocaine 2% with epinephrine
Trial: 29154063
Drug: Silymarin (420mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (420mg divided into three equal 140-mg daily doses)
Trial: 24684534
Drug: Methylphenidate 10
RxNorm normalized name: dexmethylphenidate 10.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 10 mg daily
Trial: 14969841
Drug: Intramuscular matrine
RxNorm normalized name: matrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular matrine (100 mg daily for 90 days)
Trial: 14969841
Drug: Conventional liver‐protective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional liver‐protective drugs alone (control group)
Trial: 11241028
Drug: Defined absorption
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defined absorption regions of spectra
Trial: 11241028
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of four absorption regions (nu=CH, nu(as)CH(3), nuC-O (amide I), nuC-O (carbonyle))
Trial: 9205679
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion without ibuprofen
Trial: 9205679
Drug: Saline loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline loading after ibuprofen
Trial: 7962396
Drug: Prostaglandin F2
RxNorm normalized name: Prostaglandin F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2 alpha injection
Trial: 7962396
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group identified by serum progesterone values > 20 nmol/l and daily HCG changes > +50 IU/l/day
Trial: 3304782
Drug: Human protamine
RxNorm normalized name: insulin lispro protamine, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human protamine sodium insulin 0.6 mg%
Trial: 3304782
Drug: Human isophane
RxNorm normalized name: Human isophane insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human isophane zinc insulin
Trial: 27012405
Drug: Omecamtiv Mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv Mecarbil (OM) high-dose cohort
Trial: 25656094
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (healthy individuals)
Trial: 25656094
Drug: No vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccine (healthy individuals)
Trial: 23672380
Drug: Combination feedback
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination feedback (CB)
Trial: 21039597
Drug: SRD441 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRD441 ointment
Trial: 16625109
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium containing 300 mg of iodine (Iomeron 300) at a flow rate of 3.3 mL/s
Trial: 16625109
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium containing 400 mg of iodine (Iomeron 400) at a flow rate of 2.5 mL/s
Trial: 9424839
Drug: Rehabilitation complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation complex including 'dry' effervescent baths, magnetolaser therapy applied to the heart area, cryomassage of the abdomen.
Trial: 9424839
Drug: Rehabilitation complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation complex including 'dry' effervescent baths, magnetolaser therapy applied to the heart area, cryomassage of the abdomen, plus dry air baths.
Trial: 3552295
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (35 mg acetylsalicylate per day for 7 days)
Trial: 24389518
Drug: 150 mg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg·kg(‐1) body mass tyrosine (TYR)
Trial: 20012918
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg alendronate once weekly (n = 23)
Trial: 18686766
Drug: Group 5
RxNorm normalized name: Chlamydophila psittaci biogroup 5 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 5 - blood contaminated, no post-contamination treatment
Trial: 8549578
Drug: Intense daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense daily isometric and isokinetic leg exercise
Trial: 29855386
Drug: Early motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early motion and directed exercise (EMADE) intervention consisting of a non-weight-bearing progressive home exercise programme, complemented with manual therapy and education.
Trial: 26691355
Drug: Preload (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preload (10 ml/kg crystalloid before induction)
Trial: 26691355
Drug: Coload (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coload (10 ml/kg crystalloid at the time of spinal anesthesia)
Trial: 23402713
Drug: 1% milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% milk (44 kcal/100 ml)
Trial: 23402713
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (44 kcal/100 ml)
Trial: 23402713
Drug: Regular cola
RxNorm normalized name: cola extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular cola (44 kcal/100 ml)
Trial: 21138519
Drug: Crushed lanthanum
RxNorm normalized name: lanthanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed lanthanum 1000 mg 3 times daily
Trial: 21138519
Drug: Chewed lanthanum
RxNorm normalized name: lanthanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewed lanthanum 1000 mg 3 times daily
Trial: 17302877
Drug: Oestradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol (2 x 0.1 mg/day patches) for days 5-16
Trial: 17302877
Drug: Combined Oestradiol
RxNorm normalized name: estradiol, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oestradiol + Progesterone (200 mg/day for days 13-16)
Trial: 11125410
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.05% mometasone furoate
Trial: 9767545
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (trandolapril) + calcium antagonist (verapamil)
Trial: 9767545
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (trandolapril)
Trial: 3492487
Drug: Co-trimoxazole 960
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole 960 mg
Trial: 30172098
Drug: Initial invasive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial invasive strategy (cardiac catheterization and optimal revascularization plus optimal medical therapy)
Trial: 30172098
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (optimal medical therapy alone)
Trial: 26558626
Drug: Ramosetron (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (0.3, 0.45, or 0.6 mg) administered as a single intravenous bolus 30 min before the end of surgery
Trial: 26558626
Drug: Ramosetron (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (0.3, 0.45, or 0.6 mg)
Trial: 20478446
Drug: Combination labial
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination labial plus lingual infiltration of 4% articaine with 1:100,000 epinephrine
Trial: 7691911
Drug: Theophylline (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (low concentration: 3.9 +/- 1.0 mg/liter)
Trial: 7691911
Drug: Theophylline (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (medium concentration: 8.2 +/- 1.8 mg/liter)
Trial: 7691911
Drug: Theophylline (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (high concentration: 13.2 +/- 2.3 mg/liter)
Trial: 3101537
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 (0.6-1.0 mg)
Trial: 25854014
Drug: Prozac group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prozac group (oral administration of prozac)
Trial: 21042828
Drug: Clarithromycin 200
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 200 mg/day
Trial: 16731542
Drug: Fixed appliances
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed appliances subsequent to rapid maxillary expansion (RME) and facemask therapy
Trial: 11258645
Drug: Oral creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral creatine supplements (4 x 5 g per day)
Trial: 9290397
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) doses (10, 20, 50, 100, 200, and 400 micrograms)
Trial: 8322582
Drug: Naproxen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 0.5 g daily + Paracetamol 4 g daily
Trial: 8322582
Drug: Naproxen 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1.0 g daily + Paracetamol 4 g daily
Trial: 8322582
Drug: Naproxen 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1.5 g daily
Trial: 8322582
Drug: Naproxen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 0.5 g daily
Trial: 8322582
Drug: Naproxen 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1.0 g daily
Trial: 2426830
Drug: Diltiazem infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem infusion (0.5 to 2.0 mcg/kg/min i.v.)
Trial: 16044037
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment principles
Trial: 11955536
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) administered intravenously at weeks 0, 2, and 6
Trial: 9536943
Drug: Mesalazine suppositories
RxNorm normalized name: mesalamine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine suppositories (Pentasa) 1 g three times a week
Trial: 9536943
Drug: Mesalazine suppositories
RxNorm normalized name: mesalamine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine suppositories (Pentasa) 1 g/day for relapse